Please assess the completion status of the following clinical trial:

Trial Title: S9927 Radiation Therapy After Surgery, Chemotherapy, and/or Hormone Therapy in Stage II Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed stage II adenocarcinoma of the breast (T1-2, N1, M0)~  * Primary tumor no greater than 5 cm~ * At least 1 but no more than 3 positive axillary lymph nodes~ * Nodes cannot be positive solely by cytokeratin staining~ * No apocrine, adenocystic, or squamous cell carcinomas or sarcomas of the breast~ * No bilateral breast cancer~ * No active local regional disease~* Must have undergone a modified radical mastectomy with a level I and II with or without a level III axillary dissection (at least 10 nodes examined) within the past 8 months~  * Surgical margins negative for invasive and noninvasive ductal carcinoma~ * No gross extracapsular disease or residual disease in the axilla~ * Microscopic extracapsular extension allowed~* No mastectomy after local failure following lumpectomy~* Must have received adjuvant chemotherapy and/or hormonal therapy after mastectomy~* Hormone receptor status:~  * Not specified~PATIENT CHARACTERISTICS:~Age:~* 21 and over~Sex:~* Female~Menopausal status:~* Pre- or post-menopausal~Performance status:~* Zubrod 0-1~Life expectancy:~* Not specified~Hematopoietic:~* Not specified~Hepatic:~* Not specified~Renal:~* Not specified~Other:~* Not pregnant or nursing~* Fertile patients must use effective contraception~* No other prior malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix~* No serious medical or psychiatric illness that would preclude study compliance~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* No prior trastuzumab (Herceptin)~Chemotherapy:~* See Disease Characteristics~* No more than 6 weeks since prior adjuvant chemotherapy~* No other prior chemotherapy~* Concurrent adjuvant chemotherapy allowed~Endocrine therapy:~* See Disease Characteristics~* Concurrent adjuvant hormonal therapy allowed~Radiotherapy:~* No prior chest wall or nodal radiotherapy~Surgery:~* See Disease Characteristics~* Breast reconstruction allowed~Other:~* Concurrent registration on another adjuvant chemotherapy or hormonal therapy study is allowed

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- surgery (Type: ACTIVE_COMPARATOR): surgery followed by observation
- surgery followed by RT (Type: EXPERIMENTAL): Surgery followed by radiation therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).